JAK2 and dermatitis herpetiformis, familial: The promising perspective might be the use of Ruxolitinib in both BP and DH, as Ruxolitinib inhibits JAK1 and JAK2 pathways through blocking STAT3 phosphorylation, resulting in the suppression of Th17 cell differentiation, essential in both DH and BP pathogenesis [75].